STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming

The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Just in

US judge approves $7.25 billion Roundup cancer settlement

ICE detention of Princeton scientist rattles academia

STAT+: Is MAHA’s think tank in the tank? Tax filings show low reserves

Sad, guilty and afraid of the future: young people in Colombia’s Aburrá Valley feel that climate change has taken a toll on their mental health
